205 related articles for article (PubMed ID: 9491842)
21. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
Sidi V; Roilides E; Bibashi E; Gompakis N; Tsakiri A; Koliouskas D
J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
[TBL] [Abstract][Full Text] [Related]
22. Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.
Krcméry V; Fuchsberger P; Gocár M; Salát T; Bodnárová J; Sobota R; Koza I; Svec J
Chemotherapy; 1991; 37(4):287-91. PubMed ID: 1790727
[TBL] [Abstract][Full Text] [Related]
23. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
24. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy.
Suzuki Y; Tokimatsu I; Morinaga Y; Sato Y; Takano K; Kohno K; Ogata M; Hiramatsu K; Itoh H; Kadota J
Clin Chim Acta; 2015 Feb; 440():183-7. PubMed ID: 25476135
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
[TBL] [Abstract][Full Text] [Related]
26. Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older.
Wang Y; Dai N; Wei W; Jiang C
Clin Interv Aging; 2021; 16():1023-1035. PubMed ID: 34103905
[TBL] [Abstract][Full Text] [Related]
27. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
[TBL] [Abstract][Full Text] [Related]
28. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.
Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K
Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798
[TBL] [Abstract][Full Text] [Related]
29. Mild nephrotoxicity associated with vancomycin use.
Downs NJ; Neihart RE; Dolezal JM; Hodges GR
Arch Intern Med; 1989 Aug; 149(8):1777-81. PubMed ID: 2764651
[TBL] [Abstract][Full Text] [Related]
30. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.
Cimino MA; Rotstein C; Slaughter RL; Emrich LJ
Am J Med; 1987 Dec; 83(6):1091-7. PubMed ID: 3503577
[TBL] [Abstract][Full Text] [Related]
31. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.
Pritchard L; Baker C; Leggett J; Sehdev P; Brown A; Bayley KB
Am J Med; 2010 Dec; 123(12):1143-9. PubMed ID: 21183005
[TBL] [Abstract][Full Text] [Related]
32. Vancomycin nephrotoxicity: a review.
Mergenhagen KA; Borton AR
J Pharm Pract; 2014 Dec; 27(6):545-53. PubMed ID: 25266809
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
Burgess LD; Drew RH
Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
[TBL] [Abstract][Full Text] [Related]
34. Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia.
Fullmer A; McCue D; Feng C
J Oncol Pharm Pract; 2014 Dec; 20(6):403-8. PubMed ID: 24177356
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment.
Hirai T; Hanada K; Kanno A; Akashi M; Itoh T
Eur J Clin Pharmacol; 2019 Jun; 75(6):859-866. PubMed ID: 30770940
[TBL] [Abstract][Full Text] [Related]
36. Antibiotic therapy for gram-negative bacteremia.
Calandra T; Cometta A
Infect Dis Clin North Am; 1991 Dec; 5(4):817-34. PubMed ID: 1783770
[TBL] [Abstract][Full Text] [Related]
37. Nephrotoxicity of vancomycin, alone and with an aminoglycoside.
Rybak MJ; Albrecht LM; Boike SC; Chandrasekar PH
J Antimicrob Chemother; 1990 Apr; 25(4):679-87. PubMed ID: 2351627
[TBL] [Abstract][Full Text] [Related]
38. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
[TBL] [Abstract][Full Text] [Related]
39. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
Hochart C; Berthon C; Corm S; Gay J; Cliquennois M; Tricot S; Alfandari S
Med Mal Infect; 2011 Dec; 41(12):652-6. PubMed ID: 22056376
[TBL] [Abstract][Full Text] [Related]
40. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
